Asymmetric dimethylarginine serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-a antagonist therapy.

Autores de IIS La Fe

• Joaquín Rueda Soriano

  Autor

• Carlos Gonzalez Juanatey

  Autor

Participantes ajenos a IIS La Fe

• Genre F
• López-Mejías R
• Miranda-Filloy JA
• Carnero-López B
• Gómez-Acebo I
• Blanco R
• Ochoa R
• Llorca J
• González-Gay MA

Grupos

• Hemostasia, Trombosis, Arteriosclerosis y Biología vascular

Abstract

This paper aims to determine whether disease activity, systemic inflammation and metabolic syndrome are potential determinants of circulating asymmetric dimethylarginine (ADMA) in ankylosing spondylitis (AS) patients undergoing TNF-a antagonist-infliximab-therapy.